Chronic rhinosinusitis with nasal polyps (CRSwNP) can be difficult to treat effectively in patients with aggressive or recalcitrant disease. Omalizumab (Xolair) is a monoclonal anti-IgE antibody with proven benefits for patients with moderate/severe asthma and CRSwNP, but this study looks at patients with mild asthma and CRSwNP. They used a retrospective review of notes for 23 patients treated with Omalizumab for a period between 11 and 47 months. They observed a significant improvement in reduction of nasal polyp size and in SNOT-22 scores, and the findings suggest that Omalizumab is a good treatment option for patients with mild asthma and CRSwNP.